Overview
Cognoa is a leading pediatric behavioral health company that has pioneered the first FDA-cleared AI-based diagnostic aid for Autism Spectrum Disorder (ASD), marketed as Canvas Dx. The platform leverages a sophisticated machine learning architecture designed to analyze diverse data streams, including parent/caregiver observations, physician clinical assessments, and behavioral video uploads. By 2026, Cognoa has solidified its position as the standard-of-care in primary pediatric settings, effectively bypassing the 12-18 month specialist wait times that historically delayed intervention. Technically, the system utilizes an ensemble of proprietary algorithms trained on a curated longitudinal dataset of pediatric neurodevelopmental markers. The software is classified as a Class II Medical Device (SaMD), ensuring rigorous data validation and clinical efficacy. Its 2026 market position focuses on expanding its diagnostic capabilities to ADHD and childhood anxiety, integrating directly with modern EHR systems via FHIR protocols to provide a seamless diagnostic workflow for general practitioners.